medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2009, Number 2

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2009; 22 (2)

Rho kinase inhibition as potential therapy for bronchial hyperresponsiveness

Sommer B, Carbajal V

Language: Spanish
References: 53
Page: 101-108
PDF size: 85.26 Kb.


ABSTRACT

Airway smooth muscle contraction in response to diverse stimuli diminishes patency and this issue becomes clinically important in ailments like asthma. A researchers concern is to explain if the Rho/ROCK signaling pathway might be altered in asthmatic airways. This article reviews some of the scientific literature that points out the therapeutic potential that the inhibition of the Rho/ROCK signaling pathway would have in asthmatics.


REFERENCES

  1. Chiba Y, Misawa M. The role of RhoA-mediated Ca2+ sensitization of bronchial smooth muscle contraction in airway hyperresponsiveness. J Smooth Muscle Res 2004;40:155-167.

  2. Lambert RK, Wiggs BR, Kuwano K, Hogg JC, Paré PD. Functional significance of increased airway smooth muscle in asthma and COPD. J Appl Physiol 1993;74:2771-2781.

  3. Macklem PT. A theoretical analysis of the effect of airway smooth muscle load on airway narrowing. Am J Respir Crit Care Med 1996;153:83-89.

  4. Halayko AJ, Camoretti-Mercado B, Forsythe SM, et ál. Divergent differentiation paths in airway smooth muscle culture: induction of functionally contractile myocytes. Am J Physiol 1999;276:L197-L206.

  5. Ma X, Cheng Z, Kong H, et ál. Changes in biophysical and biochemical properties of single bronchial smooth muscle cells from asthmatic subjects. Am J Physiol Lung Cell Mol Physiol 2002;283:L1181-L1189.

  6. Pfitzer G. Invited review: regulation of myosin phosphorylation in smooth muscle. J Appl Physiol 2001;91:497-503.

  7. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83:1325-1358.

  8. Kimura K, Ito M, Amano M, et ál. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996;273:245-248.

  9. Lutz S, Freichel-Blomquist A, Yang Y, et ál. The guanine nucleotide exchange factor p63RhoGEF, a specific link between Gq/11-coupled receptor signaling and RhoA. J Biol Chem 2005;280:11134-11139.

  10. Janssen LJ, Killian K. Airway smooth muscle as a target of asthma therapy: history and new directions. Respir Res 2006;7:123-134.

  11. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001;22:32-39.

  12. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 2000;261:44-51.

  13. Gosens R, Schaafsma D, Grootte Bromhaar MM, et ál. Growth factor-induced contraction of human bronchial smooth muscle is Rho-kinase-dependent. Eur J Pharmacol 2004;494:73-76.

  14. Janssen LJ, Tazzeo T, Zuo J, Pertens E, Keshavjee S. KCl evokes contraction of airway smooth muscle via activation of RhoA and Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004;287:L852-L858.

  15. Janssen LJ, Wattie J, Lu-Chao H, Tazzeo T. Muscarinic excitation-contraction coupling mechanisms in tracheal and bronchial smooth muscles. J Appl Physiol 2001;91:1142-1151.

  16. Sommer B, Montaño LM, Carbajal V, et ál. Extraction of membrane cholesterol disrupts caveolae and impairs serotonergic (5-HT2A) and histaminergic (H1) responses in bovine airway smooth muscle: role of Rho-kinase. Can J Physiol Pharmacol 2009;87:180-195.

  17. Ammit AJ, Armour CL, Black JL. Smooth-muscle myosin light-chain kinase content is increased in human sensitized airways. Am J Respir Crit Care Med 2000;161:257-263.

  18. Chiba Y, Takada Y, Miyamoto S, Mitsui Saito M, Karaki H, Misawa M. Augmented acetylcholine-induced, Rho-mediated Ca2+ sensitization of bronchial smooth muscle contraction in antigen-induced airway hyperresponsive rats. Br J Pharmacol 1999;127:597-600.

  19. Schaafsma D, Gosens R, Bos IS, Meurs H, Zaagsma J, Nelemans SA. Allergic sensitization enhances the contribution of Rho-kinase to airway smooth muscle contraction. Br J Pharmacol 2004;143:477-484.

  20. Uehata M, Ishizaki T, Satoh H, et ál. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-994.

  21. Ishizaki T, Uehata M, Tamechika I, et ál. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000;57: 976-983.

  22. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 2002;93:225-232.

  23. Yoshii A, Iizuka K, Dobashi K, et ál. Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-27632 through inhibition of Ca2+ sensitization. Am J Respir Cell Mol Biol 1999;20:1190-1200.

  24. Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 2008;48:241-247.

  25. Otsuka T, Ibuki C, Suzuki T, et ál. Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina. Coron Artery Dis 2008;19:105-110.

  26. Fukumoto Y, Mohri M, Inokuchi K, et ál. Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol 2007;49:117-121.

  27. Hinderling PH, Karara AH, Tao B, Pawula M, Wilding I, Lu M. Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract. J Clin Pharmacol 2007;47:19-25.

  28. Li F, Xia W, Yuan S, Sun R. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. Pediatr Cardiol 2009;30:363-366.

  29. Shibuya M, Suzuki Y, Sugita K, et ál. Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 1990;107:11-15.

  30. Shibuya M, Suzuki Y, Sugita K, et ál. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992;76:571-577.

  31. Vicari RM, Chaitman B, Keefe D, et ál; Fasudil Study Group. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005;46:1803-1811.

  32. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by a Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002;105:1545-1547.

  33. Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 2003;41:15-19.

  34. Inokuchi K, Ito A, Fukumoto Y, et ál. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J Cardiovasc Pharmacol 2004;44:275-277.

  35. Fukumoto Y, Matoba T, Ito A, et ál. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005;91:391-392.

  36. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E; Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 2005;238:31-39.

  37. Kishi T, Hirooka Y, Masumoto A, et ál. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 2005;111:2741-2747.

  38. Nagaoka T, Fagan KA, Gebb SA, et ál. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171:494-499.

  39. Iizuka K, Shimizu Y, Tsukagoshi H, et ál. Evaluation of Y-27632, a Rho-kinase inhibitor, as a bronchodilator in guinea pigs. Eur J Pharmacol 2000;406:273-279.

  40. Liu C, Tazzeo T, Janssen LJ. Isoprostane-induced airway hyperresponsiveness is dependent on internal Ca2+ handling and Rho/ROCK signaling. Am J Physiol Lung Cell Mol Physiol 2006;291:L1177-L1184.

  41. Hashimoto T, Nakano Y, Yamashita M, Fang YI, Ohata H, Momose K. Role of Rho-associated protein kinase and histamine in lysophosphatidic acid-induced airway hyperresponsiveness in guinea pigs. Jpn J Pharmacol 2002;88:256-261.

  42. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720-1745.

  43. Gleich GJ, Flavahan NA, Fujisawa T, Vanhoutte PM. The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. J Allergy Clin Immunol 1988;81:776-781.

  44. Costello RW, Jacoby DB, Gleich GJ, Fryer AD. Eosinophils and airway nerves in asthma. Histol Histopathol 2000;15:861-868.

  45. Lee JJ, Dimina D, Macias MP, et ál. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004;305:1773-1776.

  46. Adachi T, Vita R, Sannohe S, et ál. The functional role of rho and rho-associated coiled-coil forming protein kinase in eotaxin signaling of eosinophils. J Immunol 2001;167:4609-4615.

  47. Henry PJ, Mann TS, Goldie RG. A rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchocon striction and airways hyperresponsiveness in allergic mice. Pulm Pharmacol Ther 2005;18:67-74.

  48. Saito H, Minamiya Y, Saito S, Ogawa J. Endothelial Rho and Rho kinase regulate neutrophil migration via endothelial myosin light chain phosphorylation. J Leukoc Biol 2002;72:829-836.

  49. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 2002;80:629-638.

  50. Chiba Y, Sakai H, Misawa M. Augmented acetylcholine-induced translocation of RhoA in bronchial smooth muscle from antigen-induced airway hyperresponsive rats. Br J Pharmacol 2001;133:886-890.

  51. Chiba Y, Arima J, Sakai H, Misawa M. Lovastatin inhibits bronchial hyperresponsiveness by reducing RhoA signaling in rat allergic asthma. Am J Physiol Lung Cell Mol Physiol 2008;294:L705-L713.

  52. Takeda N, Kondo M, Ito S, Ito Y, Shimokata K, Kume H. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol 2006;35:722-729.

  53. Hirst SJ. Airway smooth muscle as a target in asthma. Clin Exp Allergy 2000;30 Suppl 1:54-59.




2020     |     www.medigraphic.com